Wide-Moat Roche Is Undervalued
The biotech giant trades at a wide discount to what we think it's worth.
We think Roche’s (RHHBY) drug portfolio and industry-leading diagnostics conspire to create sustainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare giant is in a unique position to guide global healthcare into a safer, more personalized, and more cost-effective endeavor.
In Roche’s pharmaceutical division, blockbuster cancer biologics acquired with Genentech--including Avastin, Rituxan, and Herceptin--continue to grow as they gain market share in approved indications and garner widened approval in new indications and emerging markets.
Karen Andersen does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.